LMI has been awarded the Defense Health Agency OMNIBUS IV indefinite delivery, indefinite quantity $10 billion contract in all four market segments: research and development; research and development support services; regulatory processes; and translational science support and services.
“I am proud of the value-added services and technical thought leadership, innovation, and objectivity LMI provides to the Defense Health Agency,” said LMI President and CEO Doug Wagoner. “Through assisting the DHA in addressing the complexities of medical research and development and translation science, we help improve the government’s understanding of infectious disease, genomics, emerging technology, and many other scientific fields.”
LMI provides advanced medical technology and scientific expertise support throughout the medical technology lifecycle. The company approaches the development stages from a systems engineering perspective to ensure decisions at the operational and organization levels don’t have unintended consequences elsewhere in the system.
“We are excited to take LMI’s extensive experience in medical and biotechnological portfolios and assist the DHA in meeting their goals and objectives,” said Karen LeDoux, director of LMI’s military health and veterans affairs submarket. “LMI has an incredible team of regulatory managers, clinical advisors, logisticians, scientists, and bioengineers.”
